JP2025506472A - 抗アルファシヌクレイン治療的ワクチン - Google Patents
抗アルファシヌクレイン治療的ワクチン Download PDFInfo
- Publication number
- JP2025506472A JP2025506472A JP2024547294A JP2024547294A JP2025506472A JP 2025506472 A JP2025506472 A JP 2025506472A JP 2024547294 A JP2024547294 A JP 2024547294A JP 2024547294 A JP2024547294 A JP 2024547294A JP 2025506472 A JP2025506472 A JP 2025506472A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- disease
- amino acid
- vaccine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22156006.3 | 2022-02-09 | ||
| EP22156006 | 2022-02-09 | ||
| EP22156007.1 | 2022-02-09 | ||
| EP22156007 | 2022-02-09 | ||
| PCT/EP2023/053259 WO2023152260A1 (en) | 2022-02-09 | 2023-02-09 | Anti-alpha-synuclein therapeutic vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506472A true JP2025506472A (ja) | 2025-03-11 |
| JP2025506472A5 JP2025506472A5 (cg-RX-API-DMAC7.html) | 2026-02-13 |
Family
ID=85175955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547294A Pending JP2025506472A (ja) | 2022-02-09 | 2023-02-09 | 抗アルファシヌクレイン治療的ワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250152684A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4475878A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506472A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240147981A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023219059A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248093A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002370A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR20240371A (cg-RX-API-DMAC7.html) |
| IL (1) | IL314865A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009485A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023152260A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250135293A (ko) * | 2023-01-26 | 2025-09-12 | 에이씨 이뮨 에스에이 | 리포좀 구조체 |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| AT508638B1 (de) | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| EP2659907A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| WO2013173827A2 (en) * | 2012-05-18 | 2013-11-21 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| CA3003943A1 (en) | 2015-11-03 | 2017-05-11 | Affiris Ag | Method for vaccination against a self-antigen in a human patient |
| TW202333768A (zh) * | 2017-10-25 | 2023-09-01 | 美商健生醫藥公司 | Tau胜肽之組成物及其用途 |
| MA52180A (fr) * | 2018-04-10 | 2021-02-17 | Ac Immune Sa | Vaccins thérapeutiques anti-abêta |
| JP7898188B2 (ja) * | 2020-08-04 | 2026-07-31 | エイシー イミューン ソシエテ アノニム | 免疫原性化合物 |
-
2023
- 2023-02-09 IL IL314865A patent/IL314865A/en unknown
- 2023-02-09 KR KR1020247025028A patent/KR20240147981A/ko active Pending
- 2023-02-09 EP EP23703593.6A patent/EP4475878A1/en active Pending
- 2023-02-09 JP JP2024547294A patent/JP2025506472A/ja active Pending
- 2023-02-09 AU AU2023219059A patent/AU2023219059A1/en active Pending
- 2023-02-09 CR CR20240371A patent/CR20240371A/es unknown
- 2023-02-09 CA CA3248093A patent/CA3248093A1/en active Pending
- 2023-02-09 MX MX2024009485A patent/MX2024009485A/es unknown
- 2023-02-09 US US18/836,298 patent/US20250152684A1/en active Pending
- 2023-02-09 WO PCT/EP2023/053259 patent/WO2023152260A1/en not_active Ceased
-
2024
- 2024-08-07 CL CL2024002370A patent/CL2024002370A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250152684A1 (en) | 2025-05-15 |
| IL314865A (en) | 2024-10-01 |
| EP4475878A1 (en) | 2024-12-18 |
| CR20240371A (es) | 2024-10-16 |
| CA3248093A1 (en) | 2023-08-17 |
| WO2023152260A1 (en) | 2023-08-17 |
| KR20240147981A (ko) | 2024-10-10 |
| AU2023219059A1 (en) | 2024-07-25 |
| MX2024009485A (es) | 2024-08-14 |
| CL2024002370A1 (es) | 2024-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11958889B2 (en) | Compositions of phosphorylated tau peptides and uses thereof | |
| US12324855B2 (en) | Method of safe administration of phosphorylated Tau peptide vaccine | |
| US20230257433A1 (en) | Heterologous Administration of Tau Vaccines | |
| KR102869640B1 (ko) | 항-aveta 치료적 백신 | |
| JP5474807B2 (ja) | 改変アミロイドβペプチド | |
| US20250152684A1 (en) | Anti-Alpha-Synuclein Therapeutic Vaccines | |
| US20230287050A1 (en) | Immunogenic Compounds | |
| EA051687B1 (ru) | Терапевтические вакцины против альфа-синуклеина | |
| CN118660717A (zh) | 抗α-突触核蛋白的治疗性疫苗 | |
| US20250144212A1 (en) | Liposomes containing phosphorylated tau peptides for inducing sustained immune responses | |
| HK40087814A (en) | Immunogenic compounds | |
| HK40105209A (en) | Compositions of phosphorylated tau peptides and uses thereof | |
| EA048154B1 (ru) | Иммуногенные соединения | |
| HK40039870B (en) | Compositions of phosphorylated tau peptides and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260204 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260204 |